Compare J M Smucker Co (SJM) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? J M Smucker Co trades at $119.83 (market cap $12.76B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 4.6× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.75%). Which is the better fit depends on your goals — on Pluang, investors hold J M Smucker Co for 74 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| SJM | TAK | |
|---|---|---|
Market Cap | $12.76B | $58.74B |
Volume | 1,300,545 | 3,110,994 |
Sector | Consumer Staples | Health |
52-Week High | $132.34 | $19.05 |
52-Week Low | $89.53 | $13.23 |
Typical Hold Time | 74 Days | 1 Days |
Enterprise Value | $19.61B | $86.65B |
Dividend Yield | 3.75% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $119.83, up 3.36% today, with a bullish technical signal and recent earnings beats. The company reported strong Q2 2026 EPS of $3.24 versus $2.22 expected, though 2025 net income was negative $1.23B. Valuation ratios include a P/E of 55.8 and P/S of 1.39, with analyst consensus price target at $138.23.
Outlook is positive with raised 2027 guidance, but risks include volatile profitability and high debt. The stock offers a dividend yield from the upcoming $1.12 payment, supported by institutional buying. Earnings momentum and brand strength provide upside, yet margin pressures and competitive threats remain key watchpoints.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
